 - To qualify for this study, the patient must have relapsed, refractory or previously untreated low-grade indolent non-Hodgkin lymphoma of the following subtypes: Follicular center cell lymphoma grade 1, lymphoplasmacytoid lymphoma, small lymphocytic lymphoma, splenic marginal-zone types lymphoma, monocytoid B-cell lymphoma and extranodal mucosa-associated lymphoid tissue MALT lymphomas. Final eligibility will be determined by the health professionals conducting this clinical trial. 